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12 had Marsh 2, and 2 had Marsh 1 lesions. The sever-
ity of anemia was in parallel with the severity of duode-
nal lesions. Twenty-two GSE patients (73.3%) had no 
gastrointestinal symptoms. Fourteen GSE patients who 
adhered to GFD without receiving iron supplementation 
agreed to undergo follow up visits. After 6 mo of GFD, 
their mean hemoglobin levels (Hb) increased from 9.9 ± 
1.6 to 12.8 ± 1.0 g/dL (P  < 0.01). Interestingly, in 6 out 
of 14 patients who had Marsh 1/2 lesions (e.g. no villous 
atrophy) on duodenal biopsy, mean Hb increased from 
11.0 ± 1.1 to 13.1 ± 1.0 g/dL (P  < 0.01) while they did 
not receive any iron supplementation. 
CONCLUSION: There is a high prevalence (e.g. 
14.6%) of GSE in patients with IDA of obscure origin. 
Gluten free diet can improve anemia in GSE patients 
who have mild duodenal lesions without villous atrophy.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
Gluten sensitive enteropathy (GSE) is an autoimmune 
enteropathy due to food gluten intolerance in genetically 
predisposed people[1]. While GSE was thought to be a 
rare disease in the past and was believed to be essentially a 
disease of  Europeans[2-5], recent screening studies showed 
that GSE is one of  the most frequent genetically based 
diseases which occurs worldwide, with a prevalence rang-
ing from 1:85 to 1:500 in different populations[6-9]. 
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Abstract
AIM: To determine the prevalence of gluten sensitive 
enteropathy (GSE) in a large group of patients with 
iron deficiency anemia (IDA) of obscure origin.
METHODS: In this cross-sectional study, patients with 
IDA of obscure origin were screened for GSE. Anti-
endomysial antibody (EMA) and tissue transglutamin-
ase antibody (tTG) levels were evaluated and duodenal 
biopsies were taken and scored according to the Marsh 
classification. The diagnosis of GSE was based on a 
positive serological test and abnormal duodenal histol-
ogy. Gluten free diet (GFD) was advised for all the GSE 
patients.
RESULTS: Of the 4120 IDA patients referred to our 
Hematology departments, 206 (95 male) patients were 
found to have IDA of obscure origin. Thirty out of 206 
patients (14.6%) had GSE. The mean age of GSE pa-
tients was 34.6 ± 17.03 (range 10-72 years). The female 
to male ratio was 1.3:1. Sixteen patients had Marsh 3, 
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Several categories of  GSE have recently emerged, 
including: monosymptomatic, oligosymptomatic, atypical 
(without gastrointestinal symptoms), silent, potential and 
latent form[10,11]. Iron deficiency anemia (IDA) is a com-
monly observed sign in GSE and is the only abnormality 
in 40% of  patients[12]. In fact, only a minority of  GSE 
patients present with classical malabsorption symptoms 
of  diarrhea and weight loss, whereas most patients have 
subclinical or silent forms in which IDA can be the sole 
presentation[13].
In an extensive evaluation of  the gastrointestinal 
tract in patients with IDA in order to identify a source 
of  bleeding, the origin of  bleeding cannot be detected 
in a significant minority of  patients. In some of  these 
patients IDA could be the result of  diseases that impair 
iron absorption in the absence of  bleeding[14,15]. Gluten 
sensitive enteropathy is one of  these disorders which 
causes chronic inflammation in the bowel surface, 
leading to infiltration of  T-lymphocytes, hyperplasia 
of  crypts, villous atrophy and reduction of  the bowel 
absorption surface for various nutrients such as iron[16].
Consider ing the broad spectr um of  c l in ica l 
manifestations of  GSE, including anemia, osteoporosis, 
dermatitis herpetiformis, neurologic disorders and 
life-threatening complications such as non Hodgkin’s 
lymphoma, small intestinal adenocarcinoma, esophageal 
cancer, and melanoma, early diagnosis of  GSE is 
essential[17-20].
The present study was conducted to estimate the 
prevalence of  GSE in a large group of  patients with 
IDA of  unknown origin by use of  two highly sensitive 
and specific serological tests. We also present the follow-
up data of  those GSE patients who adhered strictly to a 
GFD and agreed to undergo follow up visits.
MATERIALS AND METHODS
Subjects
In this prospective study we evaluated all 4120 patients 
with IDA referred to the Hematology departments of  
Shariati Hospital, and Firoozgar Hospital from April 
2003 to September 2007. Iron deficiency anemia was de-
fined as: hemoglobin concentration less than 13.5 g/dL 
in men and less than 11.5 g/dL in women; mean corpus-
cular volume (MCV) less than 80 fl; and ferritin level less 
than 30 ng/mL.
Methods
Patients were evaluated in 6 steps. In step 1, patients with 
the following conditions were excluded from the study: 
known malignancies, hematological diseases (hemolytic 
anemia, aplastic anemia, thalassemia and myelodysplasia), 
known chronic diseases (e.g. chronic renal failure, chronic 
infectious disease, severe cardiac and respiratory disease, 
collagen vascular disease and chronic liver disease), preg-
nancy, heavy menstrual flow (cycles ≥ 7 d), menometror-
rhagia, drug addiction, alcoholism, gastric surgery, and 
obvious blood loss (e.g. melena, hematochezia, hematuria, 
recurrent epistaxis). In this step 3559 patients were ex-
cluded and 561 were entered into the next step. 
In step 2, patients were offered the chance to par-
ticipate in the study, and a questionnaire was completed 
by each patient. Ninety-four patients declined to enter 
the study, and 467 patients entered into the next step. 
Informed consent was obtained from each patient and 
documented under institutional guidelines and oversight.
In step 3 all patients underwent colonoscopy. Pa-
tients with likely sources of  blood loss, including any 
mass lesions, polyps greater than 1.5 cm, five or more 
vascular ectasias, histologically-proven inflammatory 
bowel disease, ischemic colitis, or solitary rectal ulcer 
were excluded. In this step 108 patients were excluded, 
and 359 patients were entered into the fourth step. 
In step 4, all remaining patients underwent upper 
gastrointestinal endoscopy to exclude sources of  blood 
loss, including varices, peptic ulcer, mass lesions, polyps 
greater than 1.5 cm in diameter, five or more vascular 
ectasias, or erosive gastritis. If  none of  the above lesions 
were detected, three biopsy specimens were taken from 
the second part of  the duodenum. One hundred and 
forty seven patients were excluded in step 4. 
In step 5, the remaining 212 patients underwent 
small bowel barium study. Six patients with abnormal 
small bowel series were excluded in this step. 
Thus, from the 4120 patients with IDA who entered 
the Hematology department, 206 patients were found to 
have IDA of  obscure origin.
In step 6, venous blood samples for tissue transgluta-
minase antibody (tTG) and endomysial antibody (EMA) 
were obtained from the 206 remaining patients with 
IDA of  obscure origin. The duodenal biopsy specimens 
were fixed immediately in formalin solution for 4-8 h 
at room temperature and were routinely processed for 
conventional histological evaluation. The biopsy speci-
mens were read by one expert histopathologist and the 
histological damage of  duodenum was expressed based 
on Modified Marsh classification[3]: 0: Normal mucosal 
structure without significant lymphocytic infiltration; 1: 
Lymphocytic enteritis (more than 30 lymphocytes/100 
epithelial cells); 2: Lymphocytic enteritis and crypt hy-
perplasia; 3A: Partial villous atrophy; 3B: Subtotal villous 
atrophy.
The levels of  antibodies against IgA tTG were de-
termined by ELISA using human recombinant tTG 
as the antigen (Orgentec Diagnostika GmbH, Mainz, 
Germany). Serum samples were diluted to 1:100 with 
distilled water, incubated with antigen for 30 min at 
room temperature, washed three times, and subsequently 
incubated for another 30 min with antihuman IgA. Opti-
cal density was read at 450 nm. Results were expressed 
in arbitrary units (AU) according to the reference cali-
brator. The cut-off  value for a positive outcome was 
considered to be 10 AU, according to the instructions on 
the kit. IgA EMA assay was performed using an indirect 
immunofluorescence technique. The result was consid-
ered positive when bright green reticular fluorescence 
of  smooth muscle was detected by fluorescence micros-
copy. Total serum IgA was measured in patients with 
negative tTG and EMA results to exclude IgA deficiency 
as a cause of  false-negative tTG and EMA. 
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The presence of  positive tTG or EMA plus abnor-
mal duodenal histology (e.g. Marsh 1, 2 or 3) was de-
fined as gluten sensitivity enteropathy (GSE). All GSE 
patients were referred to our nutrition clinic and advised 
to follow a strict gluten free diet, but iron supplementa-
tion was withheld. Patients were followed up after 6 mo. 
Adherence to GFD was assessed in the follow up visit. 
Statistical analysis
Data are presented as mean ± SD or percentage. Statisti-
cal analysis was performed using SPSS software version 
15 and t-test for comparison of  the means of  quantita-
tive variables. P < 0.05 was considered statistically sig-
nificant.
RESULTS
From the 206 patients with IDA of  obscure origin, 95 
were men with a mean age of  37.6 ± 19.8 years, and 111 
were women with a mean age of  39.1 ± 14.4 years. 
Serological findings
Serological screening tests showed 31 patients had one 
or two positive tests. Twenty eight patients had positive 
tTG, and 23 had positive EMA. In 20 patients both tests 
were positive. None of  the patients with negative sero-
logical tests was IgA-deficient.
Biopsy findings
Thirty-eight patients had abnormal duodenal histology. 
Sixteen patients had Marsh 3, 15 had Marsh 2 and 7 had 
Marsh 1. Among 38 patients with abnormal duodenal 
histology, 8 patients (3 with Marsh 2, and 5 with Marsh 1) 
had negative serologic tests. Eight patients who had ab-
normal duodenal histology but negative serological tests 
were not considered to have GSE.
GSE patients
Thirty out of  206 (14.6%) of  the patients had GSE. 
The mean age of  these patients was 34.6 ± 17.03 (range 
10-72 years). The female/male ratio was 1.3:1. Thirty-
one patients were positive for one or two serologic tests, 
but one of  the tTG-positive patients had normal duode-
nal histology. Among 30 GSE patients, three had nega-
tive tTG, and seven had negative EMA. The mean dura-
tion of  anemia before the diagnosis of  GSE was 3.6 ± 1.4 
years. These patients had been treated with oral iron for 
a mean duration of  1.9 years. Anemia improved in only 
8 patients (26.8%) treated with oral iron supplementa-
tion before GSE diagnosis. Four patients (13.3%) had a 
family history of  prolonged anemia of  unknown cause 
in first degree relatives. 
Six patients (20%) mentioned flatulence, two (6.7%) 
had intermittent diarrhea and one (3.3%) had dermatitis 
herpetiformis. There were no gastrointestinal symptoms 
in 22 GSE patients (73.3%).
The mean age of  the GSE patients was not signifi-
cantly different from other IDA of  obscure origin pa-
tients (34.6 ± 17.0 vs 39.3 ± 17.1 years, respectively). 
In Table 1, mean Hb, MCV and ferritin in GSE 
patients are compared with other patients with IDA of  
obscure origin. There were no statistically significant 
differences between the patient groups. 
In GSE patients, the decrement in hemoglobin level 
was parallel to the severity of  duodenal lesion. Patients 
with Marsh 3 lesions had more severe anemia (Table 2). 
Sensitivity and specificity of the serologic tests
We calculated the sensitivity and specificity of  the sero-
logical tests based on our definition of  GSE (e.g. posi-
tive tTG or EMA, plus abnormal duodenal histology). 
The sensitivity and specificity of  IgA tTG-Ab for diag-
nosing GSE were 90% and 98.5% respectively. Also, the 
sensitivity and specificity of  EMA for diagnosing GSE 
were 76.6% and 100%, respectively. 
Follow up
All the GSE patients were referred to our Nutrition 
Clinic, and GFD was advised for all of  them. Iron 
supplementation was not started in the patients. The 
patients were invited for a follow up visit 6 mo after the 
diagnosis. 
Four GSE patients were lost to follow up. Seven 
patients did not strictly adhere to GFD. For five other 
patients, iron supplementation was started at other 
clinics during the follow up period. Thus, we present 
the follow up data of  14 patients who strictly adhered to 
GFD and did not use iron supplementation during the 
6 mo follow up period. 
Mean hemoglobin increased from 9.9 ± 1.6 to 12.8 
± 1.0 g/dL (P < 0.001), and mean serum ferritin level 
increased from 12.0 ± 6.0 to 22.1 ± 7.9 ng/mL. 
Interestingly, in 6 patients with Marsh 1/2 lesions (e.g. 
without villous atrophy) mean Hb increased from 11.0 ± 
1.1 to 13.1 ± 1.0 g/dL (P = 0.002), and mean serum fer-
ritin level increased from 16.5 ± 4.3 to 25.9 ± 6.2 ng/ml 
(P = 0.014). Demographic and clinical data are presented 
in Table 3. 
Table 1  Hemoglobin (Hb), Mean Corpuscular Volume (MCV) 
and Ferritin in GSE patients as compared with other anemic 
patients
GSE Other IDA patients1
Hb (g/dL)   9.8 ± 1.7 9.3 ± 2.0
MCV 74.0 ± 9.2 69.1 ± 12.6
Ferritin (ng/mL) 12.4 ± 9.8 11.2 ± 24.2
1P value was not significant compared to GSE patients (independent t-test).
Table 2  Mean hemoglobin level among patients with various 
degrees of duodenal lesions
MARSH classification No. of GSE patients Mean Hemoglobin level
1   2 11.2 ± 1.6
2 12  10.9 ± 1.2b
3 16    8.68 ± 1.5b,d
bP < 0.001 compared to Marsh 1 group (independent t-test), dP < 0.001 
compared to Marsh 2 group (independent t-test).
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DISCUSSION
In this prospective study, we found GSE as the cause of  
IDA of  obscure origin in a significant proportion (14.6%) 
of  patients. Various rates of  prevalence of  GSE in IDA 
patients have been reported among different studies[21-24]. 
This discrepancy may be explained by patient selection 
criteria in the different studies. 
In our study, the prevalence of  GSE is amongst the 
highest rates reported. One reason is that we evaluated 
GSE among highly selected patients in whom the cause 
of  IDA could not be identified after extensive evalua-
tion. Also, we considered patients with positive serologi-
cal tests and milder degrees of  duodenal mucosal lesions 
(e.g. Marsh 1 or 2) as having GSE.  
Physicians may fail to consider GSE as a cause of  IDA 
when gastrointestinal symptoms are absent or nonspecific. 
In this study, most GSE patients (73.3%) did not report 
any gastrointestinal symptoms. In our study, there were no 
differences in demographic characteristics or hematologi-
cal indices between GSE patients and other patients with 
anemia of  obscure origin to help to distinguish them (Table 
1). In GSE patents, the hemoglobin level was inversely 
correlated with the severity of  the histological injury. Pa-
tients with Marsh 3 lesions had the most severe anemia, 
consistent with the role of  impaired intestinal absorption 
in the pathogenesis of  IDA. We found marked improve-
ment of  anemia in 14 patients who adhered to GFD but 
did not use iron supplementation. Many authors consider 
the presence of  villous atrophy (e.g. Marsh 3) as one of  
the major criteria for diagnosing celiac disease (CD)[25,26]. 
In order to avoid this controversy in the definition of  CD, 
we used the term “gluten sensitive enteropathy” rather 
than celiac disease to describe patients with any degree of  
intestinal damage together with positive serologic tests. 
In this study, we showed a significant objective improve-
ment in hemoglobin level with GFD alone in patients 
with positive serology but no villous atrophy (e.g. Marsh 1 
or 2). Our study suggests that restriction of  the diagnosis 
of  CD to patients with overt villous atrophy will exclude 
some patients who might benefit from GFD. 
In this study, we used a human recombinant protein-
based tTG test, which has higher sensitivity and accuracy 
than a guinea pig protein-based tTG test[27]. However, 
neither tTG nor EMA was 100% sensitive. We found 
7 patients with positive tTG, negative EMA and intes-
tinal damage. On the other hand, we found 3 patients 
with negative tTG, positive EMA, and duodenal lesions. 
While some guidelines suggest that either EMA or tTG 
is sufficient for identifying patients with CD[27,28], our 
study provides evidence that both tTG and EMA should 
be used for diagnosing CD. 
In this study we did not evaluate GSE in all patients 
with IDA. One may speculate that some patients who 
were excluded before step 5, may have had GSE as well 
as another cause of  IDA. The prevalence of  GSE in 
IDA has been reported in previous studies[21-23]. In fact, 
the aim of  our study was to evaluate GSE in a large 
population of  patients with IDA of  obscure origin. In a 
population based study done in Iran, the female to male 
ratio of  GSE was 1 to 1.1[9]. Thus, the female to male ra-
tio found in our study represents the ratio of  the disease 
found in the general population of  the country. 
In conclusion, celiac disease should be considered in 
any patient with unexplained IDA, even if  they do not 
have any gastrointestinal symptoms. Furthermore, GFD 
can improve anemia in IDA patients who have positive 
tTG/EMA and mild duodenal lesions without villous 
atrophy. 
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